Immunovant Inc
(NAS:IMVT)
$
24.49
-1.24 (-4.82%)
Market Cap: 3.59 Bil
Enterprise Value: 3.30 Bil
PE Ratio: 0
PB Ratio: 7.99
GF Score: 37/100 Immunovant Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 12, 2020 / 03:15PM GMT
Release Date Price:
$49.14
(+0.02%)
Tiago Felipe Fauth;dit Suisse AG
CrÃ;Research Division - Research Analyst
© -
Everyone, welcome to the last day of our healthcare conference at Crédit Suisse. My name is Tiago Fauth, mid-cap biotech analyst here at Crédit Suisse. And I'm joined today by the Immunovant team. They're going to do a presentation. Feel free to e-mail me any questions, and I'll try to work those in towards the end.
But for now, that's it, I think. Pete, you can take it away.
Peter Salzmann
Immunovant, Inc. - CEO & Director
Super. Thanks, Tiago. Let me just share my screen here. You see that, okay?
Tiago Felipe Fauth;dit Suisse AG
CrÃ;Research Division - Research Analyst
© -
Yes.
Peter Salzmann
Immunovant, Inc. - CEO & Director
Excellent. So I just want to briefly touch on our safe harbor presentation statement. This is on our website, this entire presentation is on our website, and I will be making some forward-looking
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot